Breast Cancer and Immuno Oncology

View overview page

The Breast Cancer Channel on VJOncology is supported by Seagen.

The supporters have no influence over the production of the content.

St. Gallen Consensus 2021: neoadjuvant and adjuvant therapy for HER2+ breast cancer

Nadia Harbeck • 26 Mar 2021

Novel therapies for HER2+ metastatic breast cancer

Nadia Harbeck • 26 Mar 2021

Combined analyses of PD-L1 and TILs for therapy selection in TNBC

Sherene Loi • 22 Mar 2021

How can genomics inform treatment approaches in TNBC?

Sherene Loi • 22 Mar 2021

Immunotherapy in early-stage TNBC – where do we stand?

Sherene Loi • 22 Mar 2021

Encouraging developments in triple negative breast cancer immunotherapy

Sherene Loi • 22 Mar 2021

Next-generation antibody-drug conjugates in HER2+ breast cancer

Jean-Yves Pierga • 21 Mar 2021

Systemic therapy at the St Gallen Consensus: multi-gene testing, Ki67, and oligometastatic disease

Beat Thürlimann et al. • 22 Mar 2021

APHINITY: 6-year follow-up results of dual HER2 blockade in HER2+ breast cancer

Martine Piccart • 23 Mar 2021

Treatment advances in TNBC

Giuseppe Curigliano • 25 Mar 2021

Treating cancer during the COVID-19 pandemic

Federico Cappuzzo • 22 Mar 2021

Emerging agents in HR+ breast cancer

Sara Tolaney • 19 Mar 2021

HER2CLIMB: tucatinib efficacious against brain metastases in patients with HER2+ breast cancer

Nancy Lin • 17 Mar 2021

Can we prevent brain metastases in breast cancer?

Nancy Lin • 17 Mar 2021

Phase III trial of denosumab for breast cancer risk reduction in BRCA1 carriers

Judy Garber • 15 Mar 2021

Next questions in breast cancer treatment

Erika Hamilton • 15 Dec 2020

1
2
3
4
5
Next